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rotational atherectomy and cutting balloon
before drug-eluting stent implantation for
patients with severely calcified coronary
lesions: a pilot clinical study
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Abstract
Background: This study investigated whether, for patients with severely calcified coronary lesions, use of a cutting
balloon (CB) during rotational atherectomy (RA) before placing a drug-eluting stent will improve periprocedural
outcomes, compared to RA with a conventional plain balloon.
Methods: In a randomized controlled trial, patients with severely calcified lesions of calcium arc ≥180° were
apportioned to receive intensive plaque modification with RA and CB (RA + CB; n = 35) or RA with conventional
plain balloon (RA; n = 36). Intravascular ultrasound was applied for quantitative or qualitative analyses of
percutaneous coronary intervention outcomes. The primary outcome was acute lumen gain after drug-eluting stent.
Results: The RA + CB and RA groups were similar in baseline mean arcs of superficial calcium, and minimum lumen
cross-sectional areas (CSAs). The mean minimum stent CSA after percutaneous coronary intervention (PCI) of the RA +
CB group (5.9 ± 1.7 mm2) was significantly larger than that of the RA group (5.0 ± 1.4 mm2; P = 0.021). Patients in the
RA + CB group achieved significantly larger acute CSA gain after PCI (4.5 ± 1.5 mm2) relative to the RA group (3.8 ± 1.
5 mm2; P = 0.035). The groups were similar in rates of periprocedural complications, but at the 1-year follow-up the RA
+ CB had a lower rate of revascularization for restenosis of the target vessel and MACE (5.7 %) than did the RA group
(22.2 %, P = 0.046).
Conclusion: Aggressive plaque preparation with RA and CB seems to be safe and effective for patients with severely
calcified coronary lesions.
Trial registration: Current Controlled Trials ChiCTR-INR-16008274. Retrospectively registered 12 April 2016.
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Background
Calcification of the coronary lesion is a clinically import-
ant characteristic of coronary atherosclerosis that re-
sponds poorly to conventional percutaneous coronary
intervention (PCI) [1, 2]. Indeed, severely calcified
coronary lesions are challenging for interventional
cardiologists during the PCI process since they can
cause the balloon dilation to fail and subsequent
incomplete and asymmetrical stent expansion [3, 4].
Calcified coronary lesions are also associated with
increased risk of adverse events after PCI, such as stent
restenosis and thrombosis [5–8]. Thus, coronary calcifi-
cation warrants the development of further treatment
strategies for patients with these lesions.
During the past few decades, many novel devices and
techniques have been proposed to treat severely calcified
coronary lesions [9, 10]. The results of early observational
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studies and clinical trials suggested that modification of se-
verely calcified coronary lesions with rotational atherec-
tomy (RA) may ease the process of angioplasty and PCI
[11, 12]. Other clinical trials indicated that pre-modification
of the calcified coronary lesions with RA improved acute
periprocedural outcomes, such as acute gain of the lumen
[13, 14], with relatively few major adverse cardiovascular
events (MACE) [15]. In view of this, the guidelines for PCI
of the 2011 American Heart Association, and the American
College of Cardiology, recommend RA as an optional ther-
apy for patients with severely calcified coronary lesions
(Class IIa) [16]. Moreover, to further improve the clinical
application of RA, a standardized protocol has recently
been published by a European expert consensus [17]. How-
ever, a clinical trial published in 2013 called into question
the benefit of routine lesion preparation using RA, as it was
not associated with an improved mid-term clinical outcome
[18]. RA may not be adequate for some patients with severe
coronary calcification.
The cutting balloon (CB) has been proposed as a treat-
ment for calcified coronary lesions, but clinical evidence
is limited to a few case reports [19, 20] or observational
studies [21]. The application of the CB for angioplasty
has proved successful for treating hemodialysis access
stenosis, and the 6-month patency achieved with the CB
was significantly higher compared with balloon angio-
plasty [22]. These facts suggest that in cases of severely
calcified coronary lesions, plaque modification with both
RA and CB before drug-eluting stent implantation may
improve the PCI. Although a retrospective study implied
that RA combined with CB could have a favorable role
in lesion preparation [23], to the best of our knowledge,
there have been no relevant randomized controlled trials
published.
Therefore, we conducted a pilot randomized con-
trolled trial to evaluate the efficacy and safety of inten-
sive plaque modification with RA and CB angioplasty
before placement of a drug-eluting stent, relative to that
of RA with a plain conventional balloon. The periproce-
dural outcomes of patients with severely calcified coron-
ary lesions were confirmed on intravascular ultrasound
(IVUS).
Methods
Patients and study protocol
This study was designed as a two-center open-label
randomized controlled study to evaluate the safety and
efficacy of RA combined with cutting balloon (CB)
angioplasty, relative to conventional balloon angioplasty
(BA), for plaque modification before the implantation of
drug-eluting stents for patients with severely calcified
coronary lesions. The ethics committees of People’s
Hospital of Sichuan Province and West China Hospital
of Sichuan University, China, approved the study
protocol. All patients provided signed informed consent
before the PCI, and the patients were free to withdraw
from the study for any reason at any stage.
Inclusion and exclusion criteria
From January 2010 to September 2014, at the Cardiovas-
cular Departments of the People’s Hospital of Sichuan
Province and West China Hospital of Sichuan Univer-
sity, China, we evaluated 80 consecutive patients with 80
severely calcified coronary lesions who were scheduled
for RA, CB, or both prior to PCI and drug-eluting stent
implantation. These patients met the following inclusion
criteria of the study: with at least one severe coronary
stenosis ≥70 %, as indicated by angiography; with at least
one severely calcified lesion of the target vessels, defined
as a calcium arc of ≥180° [24]; and agreed to receive an
RA or CB-based intensive modification of the plaque be-
fore PCI.
Patients were excluded from the current study for any
of the following: acute thrombosis with unstable
hemodynamic status requiring emergent PCI; previous
PCI and presence of in-stent restenosis; extremely
tortuous or angulated lesions or lesions with dissection
before balloon expansion; lesion within a vein graft; or
other complications or comorbidities which were contra-
indicated for angiography or PCI (e.g., severe renal
dysfunction).
Randomization and treatment strategies
The included patients were randomized to either of 2
groups based on plaque modification strategies: pretreat-
ment of the severely calcified plaque with RA and subse-
quent CB (RA +CB group); or pretreatment with RA and
conventional plain balloon (RA group). The randomization
was performed according to a random sequence generated
by a computer program. No blinding was adopted in this
study. The PCI procedures and the IVUS examinations
were performed by a group of experienced physicians of
interventional cardiology.
PCI procedures
After confirmation of the diagnosis of coronary heart
disease, all of the included patients were pretreated with
aspirin or clopidogrel. A 300-mg loading dose of clopi-
dogrel was administered before the procedure if patients
were not pretreated. If they were considered to have a
heavy thrombotic burden, periprocedural glycoprotein
IIb/IIIa inhibitors were used, at the operator’s discretion.
During interventions, intravenous unfractionated hep-
arin (100 IU/kg) was administered to maintain activated
clotting time ≥300 s. A digital cardiovascular Artis zee
III ceiling-mounted Siemens system was applied for the
angiographic and PCI process. The choice of interven-
tional strategy and size of the sirolimus drug-eluting
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stent were left to the discretion of the same operator for
all patients.
An oral antiplatelet therapy regimen was implemented
in accordance with the current guidelines, i.e., a combin-
ation of aspirin and clopidogrel at least 12 months for
drug-eluting stent [16, 25]. After the PCI, cardiovascular
medications were prescribed depending on the comor-
bidities of the patients, and the post-procedural medical
therapy often included aspirin, clopidogrel, statin, beta-
blocker, angiotensin-converting enzyme-inhibitors, and
angiotensin-receptor blockers.
Description of RA and CB processes
For patients in the RA + CB group, we pretreated se-
verely calcified plaque with RA, and then subsequently
with RA, with pre-dilation of the lesion achieved with a
CB. As for patients randomized to the RA group, the
calcified lesion was pretreated with RA but only a con-
ventional plain balloon was selected for subsequent pre-
dilation.
RA was performed with a burr size of 1.25, 1.50, or
1.75 mm, and was selected to reach a burr/vessel ratio
of 0.5 (maximum: 0.7 if needed). The rotational speed of
the burr ranged from 140,000 to 180,000 rotations per
minute. The burr was platformed immediately proximal
to the lesion to avoid injury to the healthy vessel seg-
ment. Intracoronary heparin and nitroglycerin were used
to prevent any slow-flow occurring during or after RA.
For patients in both groups, the diameter of the CB or
the plain conventional balloon selected for pre-dilatation
was ≤0.5 mm that of the planned stent size, based on
the vessel media-to-media diameters determined by
IVUS. Stents were deployed after confirmation of full
balloon expansion. Non-compliant balloon postdilatation
after stenting was considered when IVUS revealed poor
stent expansion.
IVUS procedures
After conventional coronary angiography, IVUS was per-
formed at the baseline timepoint and repeated immedi-
ately after stent implantations in all cases. The IVUS
examinations were performed using a Boston Scientific
image processor iLab Ultrasound Imaging System.
Briefly, the IVUS catheter was carefully advanced distal
to the culprit lesion under fluoroscopic guidance, and
was then withdrawn automatically at 0.5 mm/s to per-
form the imaging sequence, which started 20 mm distal
to the lesion and ended at the aorto-ostial junction. For
those patients with severely narrow lesions in which
IVUS could not access the distal segment even after pre-
dilatation, the minimum lumen cross-sectional area
(CSA) was estimated as the lumen CSA of the arrival
section.
IVUS analysis
Off-line IVUS analyses were performed with the use of
Planimetry software (echoPlaque 3.0, Indec Systems).
Quantitative IVUS measurements included the diame-
ters and the CSA of the stent and the external elastic
membrane. The IVUS measurements were evaluated
based on the American College of Cardiology Clinical
Expert Consensus Document on Standards for Acquisi-
tion, Measurement, and Reporting of Intravascular
Ultrasound Studies [26].
After stent implantation, we measured the minimum
stent CSA, and the acute lumen gain was estimated as
the minimum intra-stent CSA after stenting minus the
minimum CSA before stenting.
Outcomes and clinical follow-up of the patients
The primary outcome of the study was the acute lumen
gain of the patients in the 2 groups. Also analyzed were
the RA-associated periprocedural rates of successful
stent implantation and periprocedural complications (in-
cluding coronary dissection, coronary perforation, cor-
onary slow flow or no-reflow, stent thrombosis, and
stent dislodgment), balloon dilation, and PCI.
The patients were followed for at least one year after
the PCI, and another angiographic examination was per-
formed. Major adverse cardiovascular events (MACE)
were documented including death, myocardial infarction,
and target vessel revascularization. Death included all-
cause mortality. Myocardial infarction was defined ac-
cording to current guidelines [27]. Target vessel revascu-
larization was defined as revascularization during the
follow-up period due to restenosis, either within the tar-
get lesion or within the same coronary artery.
Statistical analyses
Continuous data are presented as the mean ± standard
deviation and the categorical data are presented as num-
ber and percentage. Each set of data was subjected to a
test for normal distribution. Differences in the continu-
ous and categorical data between the 2 groups were ana-
lyzed using Student’s t-test or chi-squared analysis.
Statistical analyses were achieved with SPSS 16.0 soft-
ware (SPSS, Chicago, IL, USA). A P-value < 0.05 was
considered statistically significant.
Results
Demographic and clinical baseline characteristics of the
patients
Initially, 80 patients with coronary heart disease with se-
verely calcified lesions in the target arteries and sched-
uled to receive a selective PCI were enrolled in the
study, and were apportioned equally to the RA + CB
group or the RA group. However, 5 patients in the RA +
CB group and 4 patients in the RA group later withdrew
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from the study, for personal reasons. Finally, 71 patients
(35 in the RA + CB group and 36 in the RA group) were
included in the current analyses.
The mean age of the patients was 71.5 years, and there
were 50 men and 21 women (Table 1). All of the in-
cluded patients successfully underwent the IVUS exam-
ination and PCI, and were followed for at least 1 year.
The RA + CB and RA groups were similar for baseline
characteristics including age, gender, coronary heart dis-
ease diagnosis and risk factors, comorbidities and past
history of PCI and coronary artery bypass graft (P > 0.05,
all), except that the prevalence of chronic kidney disease
was significantly higher in the RA + CB group (28.6 %)
than in the RA group (8.3 %; P = 0.027).
Coronary lesions and the PCI procedures
The RA + CB and the RA groups were well matched for
the numbers of affected arteries, the prevalence of bifur-
cated, ostial, and chronic total occlusions, and the Me-
dina classifications of the bifurcated lesions (Table 2).
However, the percentage of patients with a left main ar-
terial lesion was significantly higher in the RA + CB
group (22.9 %) than the RA group (5.6 %, P = 0.036).
The two groups were also similar with regard to refer-
ence vessel diameter, minimal lumen diameter, total le-
sion length, and calcium length ratio, as evaluated by
IVUS before PCI (Table 3).
All of the included patients received modification of
the calcified lesions with RA, and the two groups were
not significantly different with regard to the final burr
size, or the burr-to-artery ratio (Table 2). After RA, pre-
dilations of the lesions were performed in patients of the
RA + CB and RA groups with CB and conventional plain
balloons, respectively. Balloon underexpansion was ad-
equately resolved since repeated RA was performed in
patients with balloon underexpansion, and no residual
balloon underexpansion existed for the included patients
in either group. No significant difference was detected
for maximal balloon diameters, maximal balloon infla-
tion pressures, or mean balloon inflation time for pa-
tients randomized to the two groups (Table 2).
All of the patients in both groups received successful
stent delivery. Similarly, the two groups were matched
for mean stent diameters, lengths, and stent release
pressures (Table 3). The two groups were comparable
for the proportions of patients who received post-
dilations with non-compliant balloons, the maximal bal-
loon inflation pressures, and the mean balloon inflation
time (Table 2).
Gain in acute CSA after PCI
The IVUS-evaluated mean arc of superficial calcium and
baseline minimum lumen CSA of the RA + CB group
(288.1 ± 36.3° and 1.3 ± 0.4 mm2, respectively) were sta-
tistically similar to that of the RA group (279.7 ± 47.5°
and 1.3 ± 0.4 mm2; P > 0.05, both; Table 3). However, the
minimum stent CSA after PCI of the RA + CB group
(5.9 ± 1.7 mm2) was significantly larger than that of the
RA group (5.0 ± 1.4 mm2; P = 0.021). More importantly,
patients in the RA + CB group achieved a significantly
larger acute CSA gain after PCI (4.5 ± 1.5 mm2) than did
Table 1 Baseline demographic clinical characteristics of patients in the RA + CB and RA (control) groups
RA + CB RA P
Subjects, n 35 36
Demographics Age, y 69.3 ± 11.6 72.2 ± 10.2 0.269
Male, n (%) 25 (71.4) 25 (69.4) 0.855
Body mass index, kg/m2 26.2 ± 4.9 24.8 ± 4.1 0.184
Diagnosis, n (%) Stable angina 7 (20.0) 6 (16.7) 0.717
Unstable angina 26 (74.3) 28 (77.8) 0.730
Acute myocardial infarction 2 (5.7) 2 (5.6) 0.977
Risk factors, n (%) Diabetes mellitus 25 (71.4) 27 (75.0) 0.734
Hypertension 27 (77.1) 28 (77.8) 0.949
Current smokers 20 (57.1) 22 (61.1) 0.734
Dyslipidemia 18 (51.4) 20 (55.6) 0.727
Chronic kidney disease 10 (28.6) * 3 (8.3) 0.027
LVEF < 50 % 14 (40.0) 16 (44.4) 0.705
Past history, n (%) Myocardial infarction 8 (22.9) 10 (27.8) 0.738
PCI 5 (14.3) 6 (16.7) 0.782
Coronary artery bypass graft 0 (0) 0 (0) –
*P < 0.05 compared with RA group
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Table 2 Characteristics of coronary lesions and PCI procedures of patients in the RA + CB and RA (control) groups*
RA + CB RA P
Subjects, n 35 36
Lesion location, n (%) Left main coronary artery 8 (22.9) * 2 (5.6) 0.036
Left anterior descending artery 20 (57.1) 23 (63.9) 0.561
Left circumflex artery 5 (14.3) 4 (11.1) 0.688
Right coronary 7 (20.0) 9 (25.0) 0.614
Ostial lesion 3 (8.6) 4 (11.1) 0.720
Chronic total occlusion 0 (0) 0 (0) –
Bifurcated lesion (Medina 1, 1, 1) 11 (31.4) 14 (38.9) 0.511
Bifurcated lesion (Medina 1, 1, 0) 2 (5.7) 2 (5.6) 0.977
Indications for RA Balloon catheter not passed, n (%) 20 (57.1) 22 (61.1) 0.275
Balloon catheter under expansion, n (%) 15 (42.9) 14 (38.9) 0.327
Final bur size, mm 1.58 ± 0.15 1.51 ± 0.18 0.100
Burr/artery ratio 0.56 ± 0.03 0.56 ± 0.04 0.934
Pre-dilatation after RA Pre-dilatation, n (%) 35 (100) 36 (100) 1.000
Max balloon diameter, mm 2.65 ± 0.31 2.53 ± 0.37 0.163
Max balloon inflation pressure, atm 13.8 ± 1.3 14.1 ± 1.0 0.190
Balloon inflation time, s 18.3 ± 3.6 19.7 ± 4.0 0.134
Stent implantation Stent delivery failure, n (%) 0 (0) 0 (0) __
Stent diameter, mm 2.79 ± 0.29 2.73 ± 0.37 0.418
Stent release pressure, atm 14.5 ± 1.5 14.8 ± 1.5 0.377
Post-dilatation after stent Non-compliant balloon, n (%) 28 (82.9) 31 (86.1) 0.188
Max balloon inflation pressure, atm 18.4 ± 1.7 18.8 ± 2.4 0.421
Balloon inflation time, s 20.4 ± 2.9 19.5 ± 2.4 0.210
*P < 0.05 compared with RA group
Table 3 Quantitative coronary angiography (QCA) and intravascular ultrasonographic (IVUS) analyses of lesion characteristics
RA + CB RA P
Subjects, n 35 36
Baseline Total lesion length, mm 31.3 ± 13.6 29.5 ± 13.1 0.566
Calcium length ratio 0.81 ± 0.10 0.76 ± 0.12 0.093
Superficial calcium arc 288.1° ± 36.3° 279.7° ± 41.8° 0.363
Reference vessel diameter, mm 2.8 ± 0.3 2.7 ± 0.4 0.253
Min. lumen diameter, mm 1.3 ± 0.2 1.3 ± 0.2 0.869
Reference vessel CSA, mm2 6.4 ± 1.5 6.0 ± 1.9 0.315
Min. CSA, mm2 1.3 ± 0.4 1.3 ± 0.4 0.896
Lumen stenosis rate, % 79.1 ± 4.8 77.8 ± 4.2 0.217
After stent Total stent length per lesion, mm 38.5 ± 13.1 35.8 ± 12.2 0.365
Min. stent diameter, mm 2.7 ± 0.4 2.5 ± 0.4 0.097
Min. stent CSA, mm2 5.9 ± 1.7 * 5.0 ± 1.4 0.021
Residual lumen stenosis rate, % 10.5 ± 10.4 14.7 ± 10.8 0.103
Acute CSA gain, mm2 4.5 ± 1.5 * 3.8 ± 1.5 0.035
Min minimum, CSA cross sectional area
*P < 0.05 compared with RA group
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patients in the RA group (3.8 ± 1.5 mm2; P = 0.035). This
suggests that RA combined with CB may be more effect-
ive for severely calcified lesions than RA with the con-
ventional balloon.
Periprocedural complications and follow-up results
No patient in either group experienced periprocedural
complications, including coronary perforation, stent
thrombosis, or stent dislodgment (Table 4). Three pa-
tients in each group suffered from coronary slow flow or
no-reflow; this rate was not significantly different be-
tween the 2 groups. Coronary dissection occurred in 3
patients in the RA + CB group (8.3 %) and 4 patients in
the RA group (11.1 %, P > 0.05). These results suggest
that modification of plaques with RA and CB did not
carry a higher risk of periprocedural complications than
RA with the conventional balloon.
After a mean follow-up of 13.2 ± 4.7 months, no myo-
cardial infarction, stroke, or cardiovascular death oc-
curred in patients of either group (Table 5). However,
the percentage of patients who received revasculariza-
tion for restenosis of the target vessel was significantly
higher in the RA group (22.2 %) than the RA + CB group
(5.7 %, P = 0.046) by the one-year follow-up.
Discussion
This pilot randomized controlled trial evaluated the effi-
cacy and safety of RA combined with CB for intensive
plaque modification in patients with severely calcified
coronary lesions, relative to RA with conventional bal-
loon. We found that in these patients, RA combined
with CB was associated with significantly greater acute
CSA gain (Fig. 1), and RA and CB did not carry a higher
risk of periprocedural complications during the subse-
quent PCI. This indicates that plaque modification with
RA and CB was safe for these patients. Regarding clin-
ical outcomes, at the 1-year follow-up the revasculariza-
tion for stenosis of the target vessel, and MACE,
associated with RA and CB was lower than that of RA
with conventional balloon. This suggests that RA com-
bined with CB may lead to a better clinical prognosis.
Improved acute CSA gain may be a protective factor
that prevents restenosis and MACE after PCI [28]. Our
results indicate that for patients with severely calcified
coronary lesions, intensive plaque modification with RA
and CB was safe, and was associated with improved im-
mediate PCI results compared with the RA and conven-
tional balloon. Although the potential therapeutic role of
combined plaque modification with RA and CB for pa-
tients with severely calcified coronary lesions has been
suggested in previous studies [11], to the best of our
knowledge this is the first randomized controlled trial
that confirms the efficacy and safety of this treatment
strategy under these circumstances.
A case report published in 2004 [29] reported successful
plaque modification via RA and CB prior to stent implant-
ation in a 61-year-old man with severe calcified plaque in
the ostium of the left circumflex of the left coronary ar-
tery. The combined RA and CB strategy facilitated opti-
mal stent deployment. A recent retrospective cohort study
[23] showed that RA prior to CB plaque modification for
drug-eluting stent implantation in severely calcified le-
sions appeared to be more efficacious than RA with a
plain balloon, with significantly larger final stent CSA. The
results of our present study further confirmed the previ-
ous clinical observations that intensive plaque modifica-
tion with RA and CB was associated with an improved
acute CAS gain after PCI [23] —the combined plaque
preparation strategy helped optimize the PCI, particularly
the deployment of the stents in these patients with se-
verely calcified coronary lesions.
Previous evidence showed that poor acute CSA gain after
PCI may be a predictor of increased risk for long-term
MACE [28]. The present study may be clinically important,
since it shows that intensive plaque modification with RA
and CB was associated with a lower risk of target lesion
revascularization. However, whether combined plaque
modification with RA and CB is associated with better
long-term clinical outcomes compared with RA with a
plain balloon in patients with severely calcified coronary le-
sions still needs to be determined in further studies.
Combined RA and CB plaque modification on acute
luminal gain for these patients may be of improved
Table 4 Incidences of periprocedural complications of patients
in the RA + CB and the RA control groups, n (%)
RA + CB RA P
Subjects, n 35 36
Coronary dissection 3 (8.3) 4 (11.1) 0.720
Coronary perforation 0 (0) 0 (0) –
Coronary slow flow or no-reflow 3 (8.6) 3 (8.3) 0.972
Stent thrombosis 0 (0) 0 (0) –
Stent dislodgment 0 (0) 0 (0) –
Table 5 Outcomes during the 1-year follow-up of patients in
the RA + CB and RA control groups, n (%)
RA + CB RA P
Subjects, n 35 36
Non-fatal myocardial infarction 0 (0) 0 (0) –
Non-fatal stroke 0 (0) 0 (0) –
Cardiovascular death 0 (0) 0 (0) –
Target lesion revascularization 2 (5.7) * 8 (22.2) 0.046
MACE 2 (5.7) * 4 (22.2) 0.046
*P < 0.05 compared with RA group
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benefit, compared with RA with a plain balloon, because
it overcomes the disadvantages of applying either RA or
CB alone [9, 22]. Pretreatment with RA can be limited
by the maximum burr size (1.75 mm), which may be too
small for some severely calcified lesions in vessels of
relatively large diameter; concurrent application with
CB-based plaque modification may further improve pa-
tency of these vessels. The CB catheter is relatively stiff
and non-compliant, which limits its movements through
lesions with sharp angulations. In the present study, use
of the CB was associated with better-controlled pre-
dilation of the calcified lesion, which reduced the risk of
extensive dissection caused by stretch of the arterial wall
when using the conventional plain balloon.
Interestingly, pretreatment with RA may facilitate ne-
gotiation with the CB catheters, thereby enhancing the
efficacy of the CB technique. Plaque modification with
RA and CB can optimize the deployment of the stents,
although this is also dependent on the skill of the oper-
ator, to improve the acute PCI outcome and reduce the
chances of early complications such as stent restenosis
or thrombosis induced by stent underexpansion. Obvi-
ously, the exact mechanisms underlying the immediate
benefits of combined lesion preparation with RA and CB
deserve further investigation.
Although it has been suggested that RA and CB carries
higher risks of periprocedural complications such as cor-
onary dissection or perforation, in the present study we
found that RA combined with CB was not associated with
increased risk compared with RA with a plain balloon.
Moreover, the group that received RA and CB had a lower
rate of revascularization for restenosis of the target vessel
and MACE during the 1-year follow-up, indicating that
RA and CB may lead to better clinical prognosis.
Our study is limited in that it is a pilot clinical trial,
the sample size was small, and the follow-up duration
was short. Further large-scale randomized controlled tri-
als are needed to confirm our results and explore the
potential benefits of aggressive plaque modification with
RA combined with CB for calcified lesions. In addition,
this study was designed as an open-label trial and the
baseline characteristics were not completely similar be-
tween the 2 groups. Yet, since significantly more patients
in the RA + CB group had chronic kidney disease, and
significantly more had lesions of the left main coronary
artery, and both are known predictors of poor PCI out-
comes, these imbalances did not confound the results.
Finally, due to the small sample size we were unable to
perform a subgroup analysis to explore whether patients
with certain characteristics could benefit more from the
combined plaque modification strategy. Future studies
may be needed to clarify these questions.
Conclusion
This pilot randomized controlled trial indicated that ag-
gressive plaque preparation with combined RA and CB
seems to be safe and effective for patients with severely
calcified coronary lesions, and is associated with better
Fig. 1 The angiography and intravascular ultrasound (IVUS) images of severe coronary calcification lesion before and after rotational atherectomy,
cutting balloon, and stent deployment. A1 and A2, Severe calcific stenosis of the left anterior descending artery; B1 and B2, post-rotablator; C1
and C2, post-cutting balloon; D1 and D2, post-stent
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acute PCI results and clinical outcomes compared with
RA with a conventional balloon. Future studies are
needed to confirm our results and explore the potential
long-term benefits of aggressive plaque modification
with RA combined with CB for calcified lesions.
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